166 related articles for article (PubMed ID: 38264838)
21. Batf-mediated epigenetic control of effector CD8
Tsao HW; Kaminski J; Kurachi M; Barnitz RA; DiIorio MA; LaFleur MW; Ise W; Kurosaki T; Wherry EJ; Haining WN; Yosef N
Sci Immunol; 2022 Feb; 7(68):eabi4919. PubMed ID: 35179948
[TBL] [Abstract][Full Text] [Related]
22. Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors.
Luo Q; Napoleon JV; Liu X; Zhang B; Zheng S; Low PS
Mol Cancer Res; 2022 May; 20(5):823-833. PubMed ID: 35135862
[TBL] [Abstract][Full Text] [Related]
23.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
24. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
25. Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy.
De Matteis S; Casadei B; Lolli G; Dicataldo M; Barbato F; Dan E; Paccagnella A; Sinigaglia B; Bertuzzi C; Arcari A; Zazzeroni L; Bernuzzi P; Laprovitera N; Storci G; Bertuccio SN; Ferracin M; Bonafè M; Zinzani PL; Bonifazi F
Front Immunol; 2022; 13():994731. PubMed ID: 36275688
[TBL] [Abstract][Full Text] [Related]
26. A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control.
Xin G; Schauder DM; Lainez B; Weinstein JS; Dai Z; Chen Y; Esplugues E; Wen R; Wang D; Parish IA; Zajac AJ; Craft J; Cui W
Cell Rep; 2015 Nov; 13(6):1118-1124. PubMed ID: 26527008
[TBL] [Abstract][Full Text] [Related]
27. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
28. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
29. Transcription factors in chimeric antigen receptor T-cell development.
Dai A; Zhang X; Wang X; Liu G; Wang Q; Yu F
Hum Cell; 2024 May; 37(3):571-581. PubMed ID: 38436882
[TBL] [Abstract][Full Text] [Related]
30. Harnessing the IL-21-BATF Pathway in the CD8
Topchyan P; Xin G; Chen Y; Zheng S; Burns R; Shen J; Kasmani MY; Kudek M; Yang N; Cui W
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809259
[TBL] [Abstract][Full Text] [Related]
31. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
32. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
33. The transcription factor BATF modulates cytokine-mediated responses in T cells.
Sopel N; Graser A; Mousset S; Finotto S
Cytokine Growth Factor Rev; 2016 Aug; 30():39-45. PubMed ID: 26970726
[TBL] [Abstract][Full Text] [Related]
34. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
35. The AP-1 transcription factor Batf controls T(H)17 differentiation.
Schraml BU; Hildner K; Ise W; Lee WL; Smith WA; Solomon B; Sahota G; Sim J; Mukasa R; Cemerski S; Hatton RD; Stormo GD; Weaver CT; Russell JH; Murphy TL; Murphy KM
Nature; 2009 Jul; 460(7253):405-9. PubMed ID: 19578362
[TBL] [Abstract][Full Text] [Related]
36. An NK-like CAR T cell transition in CAR T cell dysfunction.
Good CR; Aznar MA; Kuramitsu S; Samareh P; Agarwal S; Donahue G; Ishiyama K; Wellhausen N; Rennels AK; Ma Y; Tian L; Guedan S; Alexander KA; Zhang Z; Rommel PC; Singh N; Glastad KM; Richardson MW; Watanabe K; Tanyi JL; O'Hara MH; Ruella M; Lacey SF; Moon EK; Schuster SJ; Albelda SM; Lanier LL; Young RM; Berger SL; June CH
Cell; 2021 Dec; 184(25):6081-6100.e26. PubMed ID: 34861191
[TBL] [Abstract][Full Text] [Related]
37. NR4A transcription factors limit CAR T cell function in solid tumours.
Chen J; López-Moyado IF; Seo H; Lio CJ; Hempleman LJ; Sekiya T; Yoshimura A; Scott-Browne JP; Rao A
Nature; 2019 Mar; 567(7749):530-534. PubMed ID: 30814732
[TBL] [Abstract][Full Text] [Related]
38. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
39. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
40. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.
Beider K; Itzhaki O; Schachter J; Grushchenko-Polaq AH; Voevoda-Dimenshtein V; Rosenberg E; Ostrovsky O; Devillers O; Shapira Frommer R; Zeltzer LA; Toren A; Jacoby E; Shimoni A; Avigdor A; Nagler A; Besser MJ
Cells; 2022 Mar; 11(7):. PubMed ID: 35406703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
